Vanguard Global Advisers
RYTM icon

Vanguard Global Advisers’s Rhythm Pharmaceuticals RYTM Stock Holding History

Vanguard Global Advisers’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.63M Sell
23,654
-6,046
-20% -$547K ﹤0.01% 1095
2026
Q1 		$2.58M Buy
+29,700
New +$2.89M ﹤0.01% 1034

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Global Advisers's RYTM Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Rhythm Pharmaceuticals (RYTM) stake by 20% in Q2 2026, selling an estimated $547K and leaving 23,654 shares worth $2.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1095.

Vanguard Global Advisers first reported a position in RYTM in Q1 2026 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Vanguard Global Advisers held 23,654 shares of Rhythm Pharmaceuticals worth $2.63M as of Q2 2026.
  • Vanguard Global Advisers sold 6,046 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $547K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1095 holding.
  • Vanguard Global Advisers first reported a position in Rhythm Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.